Novacyt S.A. (AIM: NCYT)

Market Cap	35.89M
Revenue (ttm)	18.56M
Net Income (ttm)	-37.64M
Shares Out	n/a
EPS (ttm)	-0.53
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	22,844
Open	52.16
Previous Close	51.70
Day's Range	50.58 - 52.16
52-Week Range	42.95 - 137.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Dec 27, 2024

About Novacyt

Novacyt S.A., together with its subsidiaries, provides in vitro and molecular diagnostic tests for a range of infectious diseases in the United Kingdom, rest of Europe, France, the United States, the Asia Pacific, the Middle East, and Africa. It operates through Primer Design, and Yourgene Health segments. The Primer Design segment designs, manufactures, and markets molecular real-time qPCR testing devices and reagents in the areas of infectious diseases. The Yourgene Health segment delivers molecular diagnostic and screening solutions, across ...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2006
• Employees: 237
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: NCYT

Financial Performance

In 2023, Novacyt's revenue was 11.58 million, a decrease of -44.97% compared to the previous year's 21.04 million. Losses were -28.29 million, 9.96% more than in 2022.